TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.


Journal

Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886

Informations de publication

Date de publication:
01 2022
Historique:
received: 02 03 2021
revised: 12 08 2021
accepted: 17 08 2021
pubmed: 1 9 2021
medline: 16 2 2022
entrez: 31 8 2021
Statut: ppublish

Résumé

Mounting evidence implicates the Hippo downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in hepatocellular carcinoma (HCC). We investigated the functional contribution of YAP and/or TAZ to c-MYC-induced liver tumor development. The requirement for YAP and/or TAZ in c-Myc-driven hepatocarcinogenesis was analyzed using conditional Yap, Taz, and Yap;Taz knockout (KO) mice. An hepatocyte-specific inducible TTR-CreER We found that the Hippo cascade is inactivated in c-Myc-induced mouse HCC. Intriguingly, TAZ mRNA levels and activation status correlated with c-MYC activity in human and mouse HCC, but YAP mRNA levels did not. We demonstrated that TAZ is a direct transcriptional target of c-MYC. In c-Myc induced murine HCCs, ablation of Taz, but not Yap, completely prevented tumor development. Mechanistically, TAZ was required to avoid c-Myc-induced hepatocyte apoptosis during tumor initiation. The anti-apoptotic BCL2L12 gene was identified as a novel target regulated specifically by YAP/TAZ, whose silencing strongly suppressed c-Myc-driven murine hepatocarcinogenesis. In c-Myc murine HCC lesions, conditional knockout of Taz, but not Yap, led to tumor regression, supporting the requirement of TAZ for c-Myc-driven HCC progression. TAZ is a pivotal player at the crossroad between the c-MYC and Hippo pathways in HCC. Targeting TAZ might be beneficial for the treatment of patients with HCC and c-MYC activation. The identification of novel treatment targets and approaches for patients with hepatocellular carcinoma is crucial to improve survival outcomes. We identified TAZ as a transcriptional target of c-MYC which plays a critical role in c-MYC-dependent hepatocarcinogenesis. TAZ could potentially be targeted for the treatment of patients with c-MYC-driven hepatocellular carcinoma.

Sections du résumé

BACKGROUND & AIMS
Mounting evidence implicates the Hippo downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in hepatocellular carcinoma (HCC). We investigated the functional contribution of YAP and/or TAZ to c-MYC-induced liver tumor development.
METHODS
The requirement for YAP and/or TAZ in c-Myc-driven hepatocarcinogenesis was analyzed using conditional Yap, Taz, and Yap;Taz knockout (KO) mice. An hepatocyte-specific inducible TTR-CreER
RESULTS
We found that the Hippo cascade is inactivated in c-Myc-induced mouse HCC. Intriguingly, TAZ mRNA levels and activation status correlated with c-MYC activity in human and mouse HCC, but YAP mRNA levels did not. We demonstrated that TAZ is a direct transcriptional target of c-MYC. In c-Myc induced murine HCCs, ablation of Taz, but not Yap, completely prevented tumor development. Mechanistically, TAZ was required to avoid c-Myc-induced hepatocyte apoptosis during tumor initiation. The anti-apoptotic BCL2L12 gene was identified as a novel target regulated specifically by YAP/TAZ, whose silencing strongly suppressed c-Myc-driven murine hepatocarcinogenesis. In c-Myc murine HCC lesions, conditional knockout of Taz, but not Yap, led to tumor regression, supporting the requirement of TAZ for c-Myc-driven HCC progression.
CONCLUSIONS
TAZ is a pivotal player at the crossroad between the c-MYC and Hippo pathways in HCC. Targeting TAZ might be beneficial for the treatment of patients with HCC and c-MYC activation.
LAY SUMMARY
The identification of novel treatment targets and approaches for patients with hepatocellular carcinoma is crucial to improve survival outcomes. We identified TAZ as a transcriptional target of c-MYC which plays a critical role in c-MYC-dependent hepatocarcinogenesis. TAZ could potentially be targeted for the treatment of patients with c-MYC-driven hepatocellular carcinoma.

Identifiants

pubmed: 34464659
pii: S0168-8278(21)02016-X
doi: 10.1016/j.jhep.2021.08.021
pmc: PMC9569156
mid: NIHMS1821070
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
MYCBP protein, human 0
Transcription Factors 0
Transcriptional Coactivator with PDZ-Binding Motif Proteins 0
YAP-Signaling Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

123-134

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK026743
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204586
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239251
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250227
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Références

Cancers (Basel). 2018 Mar 20;10(3):
pubmed: 29558384
Curr Opin Cell Biol. 2017 Dec;49:99-107
pubmed: 29316535
Gastroenterology. 2014 Sep;147(3):690-701
pubmed: 24837480
Int J Mol Sci. 2020 Nov 11;21(22):
pubmed: 33187130
Gastroenterology. 2017 Feb;152(3):533-545
pubmed: 28003097
Genes (Basel). 2017 May 13;8(5):
pubmed: 28505071
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Int J Mol Sci. 2019 Feb 01;20(3):
pubmed: 30717258
Science. 2019 Nov 22;366(6468):1029-1034
pubmed: 31754005
Mol Cell Biol. 2008 Apr;28(7):2426-36
pubmed: 18227151
Genes Dev. 2012 Jun 15;26(12):1300-5
pubmed: 22677547
Mol Cell. 1999 Aug;4(2):199-207
pubmed: 10488335
Sci Signal. 2018 Sep 11;11(547):
pubmed: 30206136
Am J Pathol. 2014 Apr;184(4):912-923
pubmed: 24480331
Cold Spring Harb Perspect Med. 2014 Jul 01;4(7):a014407
pubmed: 24985130
J Hepatol. 2016 Apr;64(4):881-90
pubmed: 26639397
Cancer Res. 2011 Mar 15;71(6):2286-97
pubmed: 21262914
Am J Pathol. 2020 Jul;190(7):1397-1413
pubmed: 32283103
Mol Cell Biol. 2004 Oct;24(19):8541-55
pubmed: 15367674
Hepatology. 2017 Jul;66(1):167-181
pubmed: 28370287
Cell. 2012 Dec 21;151(7):1457-73
pubmed: 23245941
Gastroenterology. 2017 Nov;153(5):1378-1391.e6
pubmed: 28734833
Cell. 2007 Sep 21;130(6):1120-33
pubmed: 17889654
Cancer Res. 1993 Apr 15;53(8):1719-23
pubmed: 8467484
Cell Mol Gastroenterol Hepatol. 2021;11(4):1095-1117
pubmed: 33232824
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Nature. 2004 Oct 28;431(7012):1112-7
pubmed: 15475948
Br J Haematol. 2009 Apr;145(1):45-58
pubmed: 19183193

Auteurs

Haichuan Wang (H)

Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.

Shanshan Zhang (S)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.

Yi Zhang (Y)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.

Jiaoyuan Jia (J)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; Department of Oncology and Hematology, the Second Hospital, Jilin University, Changchun, China.

Jingxiao Wang (J)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.

Xianqiong Liu (X)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; School of Pharmacy, Hubei University of Chinese Medicine Wuhan, Hubei, China.

Jie Zhang (J)

Department of Thoracic Oncology II, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.

Xinhua Song (X)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.

Silvia Ribback (S)

Institute of Pathology, University of Greifswald, Greifswald, Germany.

Antonio Cigliano (A)

Institute of Pathology, University of Regensburg, Regensburg, Germany.

Matthias Evert (M)

Institute of Pathology, University of Regensburg, Regensburg, Germany.

Bingyong Liang (B)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA; Hepatic Surgery Center, Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Hong Wu (H)

Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Diego F Calvisi (DF)

Institute of Pathology, University of Regensburg, Regensburg, Germany. Electronic address: diego.calvisi@klinik.uni-regensburg.de.

Yong Zeng (Y)

Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China; Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: zengyong@medmail.com.cn.

Xin Chen (X)

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA. Electronic address: xin.chen@ucsf.edu.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH